Australia & New Zealand Autoinjectors Market Overview

The Australia & New Zealand Autoinjectors Market was valued at USD 328.10 Million in 2025 and is projected to reach USD 1,187.15 Million by 2035, growing at a CAGR of 13.72%, up from USD 203.71 Million in 2020. ANZ is the fourth-largest market in the Asia-Pacific Autoinjectors Market report with an 11.7% regional share — behind China, Japan and South Korea — and grows slightly below the regional 14.12% for the same reason Japan does: it is already the region's highest per-capita adoption cluster, with fully reimbursed biologic, insulin and emergency-epinephrine access and little untreated headroom to convert.

The Global Autoinjectors Market report singles ANZ out for a second reason: transparency. Through the NPS MedicineWise product-information system — cited repeatedly in the report for Rebif device formats and the RebiSmart multidose cartridge — ANZ is one of the most transparent markets in the world on device labelling, a useful proxy for how mature reimbursement systems handle presentation-level detail. Australia's Therapeutic Goods Administration (TGA) applies its medical-device and therapeutic-goods framework to combination products and the Pharmaceutical Benefits Scheme (PBS) publishes a price schedule including dispensed prices; New Zealand's Medsafe regulates and PHARMAC procures through fixed-budget tendering. This report quantifies the market across twelve segmentation axes and 27 segment tables with a dedicated five-region analysis.

What Shapes the ANZ Market

1. Two reimbursement systems, two price behaviours. The report's Asia-Pacific price section rates Australia's PBS schedule as a medium-transparency source — published dispensed prices, predictable listing — and New Zealand's PHARMAC schedule as low-transparency because fixed-budget tendering awards national supply to a single winner at an unpublished net price. The practical result is that Australia behaves like a European formulary market where premium device features clear listing on cost-effectiveness, while New Zealand behaves like a single-buyer tender market in which one PHARMAC decision moves the entire national volume of a molecule — and its device — in a single step.

2. Emergency epinephrine and public-access stocking. ANZ has among the highest recorded food-allergy and anaphylaxis prevalence in the world, and school, childcare and public-access epinephrine stocking is more established than in most of Asia-Pacific. The report's emergency-toxicology and public-access end-use segments are therefore proportionally larger here, and the arrival of the first needle-free epinephrine nasal spray (ARS Pharmaceuticals) is modelled as a credible route-of-administration substitute for part of that demand, as it is for the Viatris EpiPen franchise elsewhere.

3. Mature biologic and biosimilar base with a digital patient population. Fully reimbursed monoclonal-antibody therapy across rheumatology, dermatology, gastroenterology and neurology (the Rebif/RebiSmart multiple-sclerosis case the report uses as its reusable-cartridge reference), PBS listing of GLP-1 therapies, and one of the region's most digitally engaged populations make ANZ an early adopter of integrated connectivity (Asia-Pacific's fastest-growing configuration at 15.41% CAGR) and reusable platforms (15.26%). Celltrion, Samsung Bioepis and Fresenius Kabi compete on device experience in a biosimilar segment PHARMAC in particular uses aggressively.

Australia & New Zealand Autoinjectors Market by Region — In-Depth Analysis

ANZ demand follows population and hospital concentration along Australia's eastern seaboard and in New Zealand's North Island; supply is almost entirely imported, arriving through the Sydney and Melbourne distribution hubs. The regional view reads each zone against the report's drivers.

How the regional analysis is used in the report. The five-region view maps ANZ's revenue lines from the 27 segment tables onto population and hospital concentration, PBS versus PHARMAC procurement behaviour, allergy and chronic-disease prevalence and distribution geography, so that a device maker can see where a PHARMAC tender or PBS listing decides share, a biosimilar company where device experience wins switching, and a pharma partner where each modality's prescribing base sits. Quantified sub-national revenue splits (by state or territory, by country within ANZ, or by public/private channel) are available as a customization of this report — request the regional data cut here.

Australia & New Zealand Segment Insights

Growth rates shown are the Asia-Pacific values from the report's regional segment tables; ANZ's own trajectory (13.72%) runs slightly below them because it starts from the region's most mature, highest-penetration base. ANZ's distinctive mix is its anaphylaxis and public-access weighting, its reusable-cartridge heritage in multiple sclerosis, and its transparency on presentation-level labelling.

Market Drivers and Restraints in Australia & New Zealand

• Driver — mature, fully reimbursed biologic and biosimilar base. PBS and PHARMAC listing across rheumatology, dermatology, gastroenterology, neurology and endocrinology; Celltrion, Samsung Bioepis and Fresenius Kabi compete on device experience.
• Driver — anaphylaxis prevalence and public-access stocking. Among the world's highest food-allergy rates and established school and childcare epinephrine programmes.
• Driver — ageing and digital engagement. The WHO ageing driver combined with one of the region's most digitally engaged populations — early adoption of connected and reusable platforms.
• Driver — global platform supply. Ypsomed, SHL Medical, Owen Mumford, Gerresheimer and Haselmeier serve the multinational base of Novo Nordisk, Eli Lilly, Sanofi, AbbVie, AstraZeneca, UCB and CSL.
• Restraint — PHARMAC single-winner tendering. Unpublished net prices and one-decision national volume compress device economics and confine losing presentations to the private segment.
• Restraint — PBS cost-effectiveness bar. Premium features such as connectivity must clear listing on cost-effectiveness grounds, slowing uptake relative to the U.S.
• Restraint — substitution and import dependence. The first needle-free epinephrine nasal spray (ARS Pharmaceuticals) and oral GLP-1s are modelled as substitutes; with no local manufacturing, ANZ is exposed to global capacity bottlenecks and shipping disruption.

Competitive Landscape

ANZ is served by the global platform specialists — Ypsomed, SHL Medical, Owen Mumford (now part of embecta), Gerresheimer, Haselmeier, Nemera and Phillips-Medisize — and by pharma platform users Novo Nordisk, Eli Lilly, Sanofi, AbbVie, Pfizer, AstraZeneca, UCB, Merck (Rebif/RebiSmart) and CSL. Emergency epinephrine is anchored by Viatris (EpiPen) with ARS Pharmaceuticals as the needle-free challenger; biosimilar presentations come from Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris and Sandoz; Nipro, Terumo, SCHOTT Pharma and West Pharmaceutical Services anchor primary containers. The report profiles 151 companies across 15 chapters with company details, financials, product summary and recent developments.

Report Scope — Australia & New Zealand

Key Questions Answered

• How large is the Australia & New Zealand autoinjectors market and how fast will it grow to 2035 across each segmentation axis?
• How do PBS listing and PHARMAC single-winner tendering differ in the way they decide which autoinjector presentations reach patients?
• Which ANZ regions carry the deepest biologic, GLP-1 and emergency-epinephrine demand, and how does distribution geography shape supply risk?
• How large are the anaphylaxis, school and public-access segments in ANZ relative to the rest of Asia-Pacific?
• Which platform specialists, biosimilar companies and emergency-medicine suppliers are best positioned in the region's most transparent, highest-penetration market?

This country report is drawn from the Global Autoinjectors Market report. Related coverage: Asia-Pacific Autoinjectors Market report, China, Japan, South Korea, India, North America, United States, Canada, Mexico, Europe, Latin America and Middle East & Africa autoinjectors market reports.